Molecular Diagnostic Testing for Pediatric Hematological Disorders

Molecular diagnostic testing for pediatric hematological disorders uses DNA- and RNA-based technologies to identify the fusion genes, gene mutations, copy-number alterations, and hereditary variants that underpin childhood leukemias, lymphomas, hemoglobinopathies, hemophilia, and bone marrow failure syndromes. These tests support precise disease classification, risk stratification, targeted therapy selection, and minimal residual disease monitoring in children. This article explains the sample types, testing items, methodologies, clinical applications, and quality standards involved in pediatric hematology molecular diagnostics.

Technical Overview

Molecular diagnostic testing for pediatric hematological diseases refers to the laboratory analysis of nucleic acids (DNA and RNA) from blood, bone marrow, or tissue specimens in order to detect acquired (somatic) and inherited (germline) genetic abnormalities associated with blood disorders in infants, children, and adolescents. The scope covers malignant diseases such as acute lymphoblastic leukemia (ALL), acute myeloid leukemia (AML), juvenile myelomonocytic leukemia (JMML), myelodysplastic syndrome (MDS), lymphomas, and histiocytic disorders, as well as non-malignant conditions including thalassemia and other hemoglobinopathies, sickle cell disease, hemophilia, glucose-6-phosphate dehydrogenase (G6PD) deficiency, hereditary spherocytosis, aplastic anemia, and inherited bone marrow failure syndromes.

Pediatric hematologic malignancies differ biologically from their adult counterparts. Children's leukemias typically carry fewer point mutations and a higher proportion of fusion genes and copy-number alterations, and they include age-restricted entities such as infant KMT2A-rearranged leukemia and JMML driven by RAS-pathway alterations. Germline predisposition syndromes (for example, involving GATA2, SAMD9, SAMD9L, ETV6, RUNX1, CEBPA, DICER1, TP53, or Fanconi anemia genes) are also proportionally more relevant in children and have direct implications for donor selection and family counseling. Consequently, pediatric molecular test panels, detection thresholds, and interpretation frameworks must be specifically designed for younger patients.

Results are integrated with morphology, cytochemistry, immunophenotyping by flow cytometry, and conventional cytogenetics in accordance with contemporary classification systems such as the WHO Classification of Haematolymphoid Tumours and the International Consensus Classification. Molecular findings determine eligibility for targeted agents, guide risk-adapted treatment intensification or de-escalation, and provide highly sensitive markers for minimal residual disease (MRD) monitoring. Testing should be performed in clinical laboratories accredited to ISO 15189 or ISO/IEC 17025, following recognized guidance such as CLSI molecular testing standards, with variants interpreted according to ACMG/AMP and relevant somatic variant classification principles.

Testing Samples

Bone Marrow Aspirate

Bone marrow aspirate collected into EDTA anticoagulant tubes is the primary specimen for leukemia molecular workup. The first 1–2 mL of the aspirate contains the highest blast percentage and should be prioritized for molecular assays when the total obtainable volume is small, as is often the case in infants and young children. Heparin is generally avoided because it can inhibit downstream enzymatic amplification reactions.

Peripheral Blood

Peripheral blood in EDTA tubes is suitable at diagnosis when circulating blasts are present, for baseline fusion-transcript quantification, and for germline testing in selected contexts. It is the standard specimen for hemoglobinopathy genotyping, G6PD variant analysis, hemophilia A and B sequencing, and inherited bone marrow failure panel testing. Volumes as low as 0.5–1 mL are acceptable for neonates when assays are appropriately miniaturized.

Cerebrospinal Fluid and Other Body Fluids

Cerebrospinal fluid, pleural fluid, or ascitic fluid specimens (commonly 1–2 mL) may be submitted when central nervous system or extramedullary involvement is suspected. Because cell counts are low, high-sensitivity assays such as fusion-specific RT-qPCR or immunoglobulin/T-cell receptor rearrangement analysis are used to maximize yield.

Formalin-Fixed Paraffin-Embedded Tissue

Bone marrow trephine cores, lymph node biopsies, and extranodal tissue specimens fixed in formalin and embedded in paraffin can be evaluated by fluorescence in situ hybridization (FISH) and DNA-based next-generation sequencing (NGS). This is particularly useful for lymphoma-associated rearrangements and for cases in which fresh material is unavailable.

Germline Confirmation Specimens

When a hereditary predisposition syndrome or inherited marrow failure disorder is suspected, a germline control specimen is required. Cultured skin fibroblasts from a punch biopsy are the preferred gold standard, because buccal swabs and peripheral blood may be contaminated by clonal hematopoietic cells. Nail clippings are an accepted alternative for certain disorders.

Sample Handling and Transport Requirements

• Use EDTA anticoagulation for molecular assays; avoid heparinized tubes whenever PCR-based testing is planned.
• For RNA-dependent assays (fusion transcripts, RT-qPCR), transport at 2–8 °C and process within 24–48 hours to preserve transcript integrity.
• Minimize freeze–thaw cycles; aliquot specimens for parallel testing when the volume is limited.
• Label every specimen with at least two patient identifiers and maintain full chain-of-custody documentation consistent with ISO 15189 requirements.

Testing Items

Testing items for pediatric hematology molecular diagnostics fall into five major categories: fusion transcripts, somatic mutations, copy-number alterations, MRD markers, and hereditary disease variants. Representative content is summarized below.

Leukemia and Lymphoma Fusion Transcripts

• BCR::ABL1 (p190 and p210 isoforms) for Philadelphia-positive ALL and chronic myeloid leukemia.
• ETV6::RUNX1, TCF3::PBX1, and TCF3::HLF for B-cell ALL risk stratification.
• KMT2A (MLL) rearrangements with diverse partner genes in infant and therapy-related leukemias.
• PML::RARA, RUNX1::RUNX1T1, and CBFB::MYH11 for AML subtype definition.
• NUP98::NSD1, KAT6A::KAT6B, and other NUP98 rearrangements in adverse-risk pediatric AML.
• MYC, BCL2, BCL6, and ALK rearrangements in childhood lymphomas.

Somatic Gene Mutations

• RAS/MAPK pathway: PTPN11, KRAS, NRAS, NF1, and CBL alterations characteristic of JMML.
• JAK/STAT pathway: JAK1, JAK2, JAK3, IL7R, and SH2B3 alterations in B-ALL, including Ph-like ALL.
• B-cell development genes: IKZF1, PAX5, and ETV6 deletions or sequence mutations.
• AML-associated genes: FLT3 (ITD and TKD), NPM1, CEBPA, WT1, KIT, and GATA2.
• Histiocytosis-associated genes: BRAF V600E, MAP2K1, MAP3K1, and ARAF.
• Tumor suppressor and predisposition genes: TP53 and RB1 where clinically indicated.

Copy-Number Alterations

Targeted assays detect intrachromosomal amplification of chromosome 21 (iAMP21), CDKN2A/B deletions, ETV6 and PAX5 deletions, monosomy 7, and gains such as trisomy 4 and trisomy 10, all of which carry prognostic significance in childhood acute leukemias.

Minimal Residual Disease Markers

MRD tracking relies on patient-specific immunoglobulin (IGH, IGK, IGL) and T-cell receptor (TRG, TRD, TRB) rearrangements, quantifiable fusion transcripts, and recurrent point mutations. NGS-based clonality assays now extend sensitivity to the 10⁻⁵ to 10⁻⁶ range.

Inherited Hematological Disease Variants

• Hemoglobinopathies: HBB variants (HbS, HbE, HbC, beta-thalassemia mutations) and HBA1/HBA2 deletions or point variants causing alpha-thalassemia.
• Red cell enzymopathies: G6PD and PKLR variant detection.
• Red cell membrane disorders: SPTA1, SPTB, ANK1, EPB42, and SLC4A1 variants underlying hereditary spherocytosis and elliptocytosis.
• Coagulation disorders: F8 intron 22 and intron 1 inversions plus sequence variants for hemophilia A; F9 variants for hemophilia B; VWF variants for von Willebrand disease.
• Bone marrow failure and predisposition syndromes: FANC-complement genes, DKC1, TERT, TERC, RTEL1, ribosomal protein genes (RPS19, RPL11, RPL35A), ELANE, SBDS, GATA2, SAMD9, SAMD9L, RUNX1, ETV6, ANKRD26, and WAS.

Testing Methods

Karyotyping and FISH

Conventional G-banded karyotyping provides a genome-wide view of numeric and structural chromosomal abnormalities, while FISH delivers rapid (typically 24–72 hours), targeted confirmation of specific rearrangements, deletions, or amplifications such as iAMP21, using bone marrow smears, aspirate pellets, or paraffin sections.

PCR-Based Methods

• Reverse-transcription quantitative PCR (RT-qPCR) quantifies fusion transcripts at diagnosis and serially during therapy for MRD assessment.
• Multiplex RT-PCR screening panels detect dozens of common fusion transcripts simultaneously from limited RNA input.
• Gene scanning and fragment analysis identify clonal immunoglobulin and T-cell receptor rearrangements as patient-specific MRD targets.
• Allele-specific PCR and digital droplet PCR (ddPCR) achieve sensitivities of 0.01–0.001% for hotspot or low-level variants.

Sanger Sequencing

Sanger sequencing remains a reliable, cost-effective method for single-gene testing and family segregation studies, such as HBB variant confirmation in thalassemia carriers or F9 sequencing in hemophilia B families, and for orthogonal confirmation of NGS findings.

Next-Generation Sequencing

Targeted NGS panels—designed as amplicon-based or hybrid-capture assays covering 50 to more than 400 genes—are the mainstay of contemporary pediatric leukemia and marrow failure workups, with typical limits of detection of 2–5% variant allele fraction. Whole-exome and whole-genome sequencing, ideally with trio analysis including both parents, are applied in genetically heterogeneous inherited disorders. NGS-based MRD assays track clonal rearrangements with sensitivity down to one cell in a million.

Copy-Number and Structural Analysis

Multiplex ligation-dependent probe amplification (MLPA) is the reference method for alpha-thalassemia deletion screening and exon-level deletion detection, while array comparative genomic hybridization and SNP arrays provide genome-wide copy-number and copy-neutral loss-of-heterozygosity profiles.

Quality Assurance

All methodologies should be analytically validated for accuracy, precision, sensitivity, and reportable range in accordance with ISO 15189 or ISO/IEC 17025 requirements and CLSI molecular methods guidance. Participation in external proficiency testing programs, standardized bioinformatics pipelines, and structured variant interpretation under ACMG/AMP and somatic classification frameworks ensure consistent, clinically actionable reporting.

Applications

Diagnostic Classification and Risk Stratification

Molecular results assign leukemias to defined entities under current WHO and International Consensus classifications. Favorable-risk markers such as ETV6::RUNX1, and adverse markers such as KMT2A rearrangements, TCF3::HLF, iAMP21, and IKZF1 deletions, directly determine whether a child receives standard or intensified therapy.

Therapy Selection and Monitoring

BCR::ABL1 positivity qualifies children for ABL-class tyrosine kinase inhibitor therapy combined with chemotherapy; JAK-pathway alterations identify candidates for JAK inhibitor trials; FLT3 and other targets inform AML management. Serial molecular MRD monitoring at defined treatment timepoints predicts relapse risk, guides chemotherapy intensification, and informs hematopoietic stem cell transplantation decisions.

Inherited Blood Disorder Management

Genotyping enables carrier screening for thalassemia and hemoglobinopathies, confirmation of newborn screening results, prenatal diagnosis, and preimplantation genetic testing. In hemophilia, molecular results predict inhibitor risk, support carrier detection, and guide genetic counseling.

Predisposition Surveillance and Family Evaluation

Identification of germline variants in genes such as GATA2, SAMD9L, RUNX1, ETV6, or CEBPA triggers hematologic surveillance programs, directs avoidance of affected sibling donors at transplant, and enables cascade testing of relatives.

Resolving Diagnostically Ambiguous Cytopenias

In children with persistent unexplained cytopenia, molecular testing helps distinguish reactive conditions, inherited marrow failure, and early clonal disorders, preventing both undertreatment and unnecessary exposure to toxic chemotherapy.

FAQ

Q: What is the difference between molecular testing and conventional chromosome analysis? A: Karyotyping examines whole chromosomes at low resolution in dividing cells, whereas molecular assays such as FISH, PCR, and NGS detect submicroscopic fusion genes, mutations, and copy-number changes at much higher sensitivity, often without requiring viable dividing cells. The methods are complementary and are usually performed together.

Q: How much blood or marrow does a young child need to provide? A: Validated pediatric protocols typically require 1–2 mL of EDTA bone marrow or 0.5–5 mL of peripheral blood depending on the assay. Miniaturized extraction and multiplex NGS workflows allow comprehensive testing even from neonatal volumes.

Q: How long do results take? A: Typical turnaround times are 2–5 days for FISH, 3–7 days for RT-qPCR fusion quantification, 7–14 days for targeted NGS panels, and 3–6 weeks for whole-exome or whole-genome studies with trio analysis.

Q: Does a negative molecular test exclude a blood disorder? A: No. A negative result reduces the probability of the targeted abnormalities but cannot exclude disease caused by variants outside the assay scope. Final diagnosis always integrates molecular data with morphology, immunophenotyping, and clinical findings.

Q: What is the sensitivity of molecular MRD testing? A: RT-qPCR and NGS-based MRD assays routinely reach sensitivities of 10⁻⁴ to 10⁻⁶, meaning one leukemic cell can be detected among 10,000 to 1,000,000 normal cells, substantially exceeding morphologic assessment.

Q: Are detected variants always inherited? A: No. Most leukemia-associated variants are somatic and confined to blood cells. When a predisposition gene is mutated, germline status should be confirmed using cultured skin fibroblasts before family counseling and donor selection decisions are made.

Q: Can molecular testing assist future pregnancies in families with hemoglobinopathy or hemophilia? A: Yes. Carrier screening, prenatal diagnosis, and preimplantation genetic testing are well-established applications that rely on accurate familial variant characterization, ideally after proband sequencing has identified the family-specific variant.

Q: Where should such testing be performed? A: Testing should be conducted in accredited third-party laboratories or hospital molecular diagnostics laboratories holding ISO 15189 or ISO/IEC 17025 accreditation, with validated pediatric assays, qualified genetic counseling support, and documented participation in external quality assessment schemes.